Market Pulse Breaking News Alert for Friday, March 4, 2005: MTNU - Martin Nutraceuticals - Provides Conclusive Results of Joint Therapy Formula!

Market Pulse News Alert for this AM, Stocks to Watch are: Martin Nutraceuticals, Inc. (OTC: MTNU), Oracle Corp. (NASDAQ: ORCL), Cisco Systems Inc. (NASDAQ: CSCO), and Closure Medical Corp. (NASDAQ: CLSR).

Investors need to be watching Martin Nutraceuticals, Inc. (OTC: MTNU) this AM! Martin Nutraceuticals is a company focused on developing natural and alternative medicine products that provide better health for individuals through the use of their wide range of products. The flagship product which is based on Joint Therapy is used to aid in joint and general arthritic pain. Over $3.9 billion is spent on over-the-counter and prescription medication for arthritis, joint and muscle related pain in North America alone! Dr. Martin's products have amassed sales of over $35 million! MTNU had great news out before today's opening bell regarding providing conclusive results of a joint therapy formula! Investors should be watching this one closely!

Martin Nutraceuticals, Inc. (OTC: MTNU) today commented on a recent report from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, which reported that one in seven Americans suffer from some sort of Arthritic pain. It is estimated that over 40% of North Americans suffer from severe disabling of the joints or muscle pain that severely affects their quality of life.

Currently in North America, over $3.9 billion is spent on over the counter and prescription medication for arthritis, joint and muscle related pain. Many of these products come with serious and even deadly side-effects, most recently cited -- VIOXX and other Non-Steroidal Anti-Inflammatory drugs.

Last year, North Americans spent approximately $400 million on Glucosamine supplements that have proven to reduce pain, but only in large joints such as the knee and the hip. Glucosamine is ineffective at reducing inflammation and unlike Dr. Martin's enzyme formula, does nothing for muscle pain.

Perhaps one of the biggest disadvantages surrounding the use of Glucosamine and Chondroitin Sulfate is the lengthy reaction time that is required before any effect has taken place, if any has at all. Glucosamine and Chondroitin Sulfate have been well documented to show that less than 50% of those taking these supplements notice any difference in their joint pain and for others, expecting relief can surpass 18 months in waiting time.

For several years, Dr. AW Martin, DC, PhD, RNCP, DNM, a Canadian researcher has studied the effects of enzyme therapy on pain and inflammation. Dr. Martin has developed a unique blend of proprietary and patented "systemic oral enzymes" designed to provide superior anti-inflammatory benefits. Studies have shown that Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain and inflammation in 80% of patients who are diagnosed with Osteoarthritis of the knees in less than 6 weeks. Within this test group, 20% described their relief as dramatic with almost complete relief of all pain and swelling.

In another study conducted for patients suffering with Fibromyalgia -- a severe muscle pain syndrome that effects more than 20 million North Americans -- 90% of patients reported relief from swelling and pain within 4 weeks of using Dr. Martin's Joint Therapy formula.

Martin Nutraceuticals' Joint Therapy is an all-natural unique blend of system enzymes designed to provide superior anti-inflammatory benefits by breaking down harmful protein and facilitating its removal from the body. Martin Nutraceuticals Joint Therapy has also shown to have an affect on improving blood flow and regulating the immune system, resulting in a faster healing process.

Martin Nutraceuticals is just concluding launch plans for the Joint Therapy product into the United States and Canada for the second quarter of 2005.

Stocks acting well as of late include: Oracle Corp. (NASDAQ: ORCL), Cisco Systems Inc. (NASDAQ: CSCO), and Closure Medical Corp. (NASDAQ: CLSR).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.